LENA DEGLING WIKINGSSON

Chairman

Lena Degling Wikingsson is a pharmacist by training and holds a PhD in Pharmaceutical Science. She has over 20 years of experience in the pharmaceutical industry and has previously been CEO of Independent Pharmaceutica AB and Avaris AB, a non-executive Director of Avaris AB, held positions at SBL Vaccines, Accuro Immunology, and worked as a biotechnology assessor at the Medicinal Products Agency. She has broad experience in regulatory affairs and development of biologics and vaccines. Lena Degling Wikingsson is currently non-executive Director of Simplexia and CEO of Dilafor AB.

GUNNAR MATTSON

Gunnar Mattsson is Partner of Advokatfirman Lindahl, one of Sweden’s largest law firms, since 1994. Head of Lindahl’s life sciences practice 2009-2014. Internationally ranked as a leading lawyer within life sciences. Extensive experience as director of public and private companies within pharmaceuticals and biotechnology.

HANS GUSTAF LJUNGGREN

Hans-Gustaf Ljunggren serves as a Professor at Karolinska Institutet and is the Founder of the Centre for Infectious Medicine (CIM) and former Dean of Research at Karolinska Institutet. He has a long background in NK cell-related research including NK cell-based cancer immunotherapy. Since 2020, he is the Director of the Vinnova Competence Center NextGenNK, focusing on the development of next generation NK cell-based immunotherapies. He serves on several Boards and SABs in the area of cancer immunotherapy. He is a member of the Nobel Assembly of the Karolinska Institutet.

AGNETA EDBERG

Agneta Edberg, has over 25 years’ experience from leading positions in life science industry. She has been CEO at Mylan AB and the Swedish Pharmaceutical Insurance and has held leading positions within Pfizer, Bactiguard och Cilag (Johnson & Johnson). Agneta has between 2010 – 2018 been chairman of the board of Immunicum AB a company active within immune oncology and listed on the Stockholm Stock Exchange. She is also chairman of the board of Idogen AB and participate on the board of the VINNOVA project CAMP, Centre for Advanced Medical Products to cover the needs of SMEs. Since 2020, she participate on the board of the Vinnova Competence Center NextGenNK, focusing on the development of next generation NK cell-based immunotherapies.

JOHAN LIWING

CEO

Johan Liwing, has over 15 years’ experience from leading positions within the life science industry in Sweden as well as internationally. During his 13 years at Janssen (Johnson & Johnson) he held various positions in health economics, sales & marketing as well as observational research with increased responsibilities. In his last position at Janssen, as global senior director, he was responsible for developing the use of observational data. Johan has also worked for Roche as well as in other areas outside the life science industry, such as finance and engineering.

KARIN MELLSTRÖM

Senior Advisor

Dr. Mellström has over 20 years of experience from the Life Science Industry. She acted as a Senior project manager and Head of cell biology departments at KaroBio AB  as well as KabiGen. She has been a project leader at Avaris AB and held a project coordinator position at Karolinska University Hospital and Karolinska Institutet with the aim to facilitate the development of cell therapies. She has vast experience  from project management, drug development and clinical trials and has been involved in several international collaborations with Big Pharma.

EVREN ALICI

Scientific Advisor

Evren Alici is a senior scientist and the group leader of the Cell and Gene Therapy Group, HERM, Department of Medicine, Karolinska Institutet. Evren received his MD at Ege University in 1999 and received his PhD from Karolinska Institutet in 2006. Evren’s main research interests are natural killer cells, multiple myeloma, lentiviral and retroviral gene transfer, stem cell transplantation and immunology.

HARETH NAHI

Clinical Advisor

Hareth Nahi is a senior consultant hematologist and senior lecturer at KI. He is a senior scientist and the group leader of the multiple myeloma research group, HERM, Department of Medicine, Karolinska Institutet. Hareth received his MD at Uppsala University in 1996 and received his PhD from Karolinska Institutet in 2007. Hareth’s main research interests are multiple myeloma, 1^st in human clinical trials, stem cell transplantation and immunology. He is the current vice and former president of NMSG (Nordic Myeloma Study group)

MARKUS LAGERLÖF

CIO

Markus Lagerlöf has an MSc in Industrial Engineering and Management from Linköpings Tekniska Högskola, Sweden. More than 20 years of Life Science experience in Pharma/Life Science at Pfizer, Novartis, GSK, GE Healthcare, Sandoz within sales, marketing, strategy, M&A, business development and management. Since 2015 solely focusing on financing across the ECM vis-à-vis Life Science at Stockholm Corporate Finance. Has worked with global, regional – including CEE/Russia – and local responsibilities in New York, London, Munich, Stockholm and Uppsala.

VERA FRANZÉN

Regulatory Advisor

Vera Franzén has long experience from the Swedish pharmaceutical industry, working in senior positions within pharmaceutical development, quality control and regulatory affairs. For four years, Vera was Head of Section, Procedure Co-ordination, at the MPA and represented Sweden in the CMDv. Vera has a great interest in ATMPs. She has worked in one of the first ATMP companies in Sweden and is a CAT Interested Party. Nine years ago, Vera started her own consulting company and is engaged in several ATMP projects. Vera is a member of the TOPRA Editorial Team for the Regulatory Rapporteur and a member of the working party of TOPRA in Sweden. She also gives presentations on European pharmaceutical legislation on a regular basis at courses arranged by The Swedish Academy of Pharmaceutical Sciences.

HANS ERICSON

CFO

Senior Finance professional with more than 20 years’ experience in International business and dynamic environment. Results Oriented and business minded with a ‘helicopter view’. Hands-On and proven leadership in Controllership and Finance. Strong skills in controlling and good understanding in accounting.